Denosumab(Synonyms: Immunoglobulin G2; Ranmark)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Denosumab (Synonyms: Immunoglobulin G2; Ranmark)

Denosumab 是一种人单克隆抗体，结合并抑制 RANKL 受体激活因子 (TNFSF11)。Denosumab 可以降低椎骨、非椎骨和髋部骨折的风险，也具有抗癌活性。

Denosumab(Synonyms: Immunoglobulin G2; Ranmark)

Denosumab Chemical Structure

CAS No. : 615258-40-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures[1], also has anti-cancer activity[2].

分子量

144716.86

Formula

C6404H9908N1724O2004S50
CAS 号

615258-40-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.

    [2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务